无效与有害再灌注:卒中治疗效应与总体结局的平衡
该文批判性审视了缺血性卒中研究聚焦快速再灌注、主张对所有病例行再灌注的观点。作者提出两点警示:个体患者再灌注未必转化为有意义的改善,无效再灌注确实存在;少数患者再灌注可能主动恶化结局,即有害再灌注。应超越仅关注血管再通的一刀切模式,借助先进影像与大规模数据预测获益、无效与有害再灌注。
要点
- 试验报告的是平均效应,个体结局范围更宽,无效再灌注确实存在。
- 基线预后越差,绝对获益可能低于干预不再合理的阈值,尽管相对效应有利。
- 少数患者再灌注可能有害,不应以高风险人群额外伤害可忽略为由鼓励治疗激进主义。
核心结论
- 再灌注并非在所有患者中均转化为有意义的改善,无效再灌注真实存在。
- 少数患者再灌注可能主动恶化结局,即有害再灌注。
- 应超越仅关注血管再通的一刀切再灌注模式,细化患者选择。
研究设计与样本
- 本文为针对缺血性卒中再灌注策略的批判性论述,未报告原始研究设计与样本量。
主要发现
- 血管内取栓已革新大血管闭塞治疗范式,近期试验显示即使在基线大核心患者中也有获益。
- 部分观点主张无论梗死体积与严重程度均行再灌注,作者对此提出两点警示。
- 试验结果常以相对而非绝对治疗效应报告,基线预后恶化时绝对良好结局可能性可能降至干预不再合理的阈值以下。
关键数值与推荐
- 部分患者梗死可能过大(如>150 mL)、缺血过重(如平扫CT严重低密度)或合并症压倒任何潜在获益。
- 需更好理解组织活力、灌注生理与缺血损伤,以细化患者选择。
临床怎么用
- 临床不应仅以血管再通为目标,需综合评估梗死体积、缺血严重程度与合并症。
- 应利用先进影像与大规模数据集开发模型,预测获益、无效与有害再灌注。
局限性
- 本文为观点性论述,未提供原始研究数据或系统检索范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decades, ischemic stroke research has primarily focused on achieving rapid reperfusion. Endovascular thrombectomy has revolutionized the treatment paradigm for patients with large vessel occlusion, with recent trials showing benefit even in patients with large core at baseline. These findings have led some to advocate for reperfusion in all cases, regardless of infarct size and severity. We critically examine this line of reasoning and introduce 2 important caveats. First, in an individual patient, reperfusion does not necessarily or uniformly translate into meaningful improvement and favorable outcomes. The concept of futile reperfusion is real. As a corollary, trial results capture average effects, and individuals have a wider range of outcomes. Furthermore, results are often reported as relative rather than absolute treatment effects. As baseline prognosis worsens, the absolute likelihood of a good outcome may fall below a threshold where the intervention is no longer justified, despite a favorable relative treatment effect. Second, in a small subset of patients, reperfusion may actively worsen outcome; this is harmful reperfusion. While additional harm may seem negligible in such a high-risk population, this rationale is flawed as it encourages therapeutic actionism and violates the foundational medical ethical principle of primum non nocere. To advance patient care, we must move beyond a one-size-fits-all reperfusion model that focuses only on vessel reopening. Some patients might have infarcts that are simply too large (eg, >150 mL), ischemia that is too severe (eg, severe noncontrast computed tomography hypodensity), or comorbidities that overwhelm any potential benefit. A more nuanced approach requires a better understanding of tissue viability, perfusion physiology, and ischemic damage. This would allow for refined patient selection by leveraging advanced imaging and large-scale data sets to develop accurate models to predict treatment effect, that is, beneficial, futile, and harmful reperfusion.
引用
- Pensato U, Hill MD, Menon BK, et al. Futile and Harmful Reperfusion and the Balance Between Treatment Effect and Overall Outcomes in Stroke. Stroke. 2025. PMID: 41144588. doi:10.1161/STROKEAHA.125.053226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。